BioMarin to Present at the Jefferies Healthcare Conference

NOVATO, Calif., June 10 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc.
(Nasdaq: BMRN) today announced that Steve Aselage, Senior Vice President and
Chief Business Officer of BioMarin, will present a company update at the
Jefferies Healthcare Conference in New York City on Wednesday, June 17, 2009
at 8:30 a.m. ET.

Interested parties may access a live audio webcast of the conference call via
the investor section of the BioMarin website, www.BMRN.com. A replay of the
call will be archived on the site for one week following the call.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious
diseases and medical conditions. The company's product portfolio comprises
three approved products and multiple clinical and pre-clinical product
candidates. Approved products include Naglazyme(R) (galsulfase) for
mucopolysaccharidosis VI (MPS VI), a product wholly developed and
commercialized by BioMarin; Aldurazyme(R) (laronidase) for
mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a
50/50 joint venture with Genzyme Corporation; and Kuvan(R) (sapropterin
dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership
with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other
product candidates include PEG-PAL (PEGylated recombinant phenylalanine
ammonia lyase), which is currently in Phase I clinical development for the
treatment of PKU and GALNS (N-acetylgalactosamine 6-sulfatase), which is
currently in Phase I/II clinical development for the treatment of MPS IVA. For
additional information, please visit www.BMRN.com. Information on BioMarin's
website is not incorporated by reference into this press release.

BioMarin(R), Naglazyme(R) and Kuvan(R) are registered trademarks of BioMarin
Pharmaceutical Inc.

Aldurazyme(R) is a registered trademark of BioMarin/Genzyme LLC.

Contacts:

Investors Media
Eugenia Shen Susan Berg
BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc.
(415) 506-6570 (415) 506-6594

SOURCE BioMarin Pharmaceutical Inc.

investors, Eugenia Shen, +1-415-506-6570, or media, Susan Berg,
+1-415-506-6594, both of BioMarin Pharmaceutical Inc.